Literature DB >> 1547372

Two-color flow cytometric analysis of splenic lymphocyte subpopulations in patients with gastric cancer.

M Takahashi1, S Fujimoto, M Takai, K Ohno, F Endoh, Y Masuda, Y Masuda, G Obata.   

Abstract

Lymphocyte subpopulations of the spleen were assayed in 26 patients with gastric cancer and 5 patients with benign disease using two-color flow cytometric analysis. The ratio of Leu 2a+.Leu 15+ cells, or suppressor T cells, in the gastric cancer patients was about 6 per cent, being higher than that in the patients with benign disease (p less than 0.05). There were fewer Leu 7+.Leu 11- cells, or natural killer-NK-cells, in the gastric cancer patients in stage III or IV than in those with stages I or II (p less than 0.05). The ratio of Leu 3a+.Leu 8- cells, or helper T cells, in the stage IV patients accounted for about 15 per cent of the splenic lymphocytes, which was less than that seen in the patients in stages I or II (p less than 0.05). The ratio of Leu 2a+.Leu 15- cells, or cytotoxic T cells, was approximately twice that of suppressor T cells. The pre-operative administration of lentinan plus OK-432 increased the ratio of Leu 4+.HLA-DR+ cells, or activated T cells, and cytotoxic T cells (p less than 0.05 and p less than 0.01, respectively). The above results suggest that lymphocyte subpopulations in the spleen may have more immunosuppressive potential in proportion with the stage of gastric cancer, but that this reduced immune state may be altered when lentinan and OK-432 are given to these patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1547372     DOI: 10.1007/bf00326123

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  25 in total

1.  Role of the spleen in passive immunological enhancement.

Authors:  J F Ferrer
Journal:  Transplantation       Date:  1968-03       Impact factor: 4.939

2.  Serum mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas.

Authors:  I Hellström; K E Hellström; H O Sjögren
Journal:  Cell Immunol       Date:  1970-05       Impact factor: 4.868

Review 3.  Immunobiological consequences of splenectomy: a review.

Authors:  M Llende; E A Santiago-Delpín; J Lavergne
Journal:  J Surg Res       Date:  1986-01       Impact factor: 2.192

4.  Characterization of human lymphocyte subpopulations: alloreactive cytotoxic T-lymphocyte precursor and effector cells are phenotypically distinct from Leu 2+ suppressor cells.

Authors:  L T Clement; M K Dagg; A Landay
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

5.  Splenic regulation of the clinical appearance of small tumors.

Authors:  J J Nordlund; R K Gershon
Journal:  J Immunol       Date:  1975-05       Impact factor: 5.422

6.  Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression.

Authors:  E L Reinherz; P C Kung; J M Pesando; J Ritz; G Goldstein; S F Schlossman
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

7.  Effect of splenectomy in tumor-bearing mice and gastric cancer patients.

Authors:  K Orita; E Konaga; T Okada; K Kunisada; M Yumura; S Tanaka
Journal:  Gan       Date:  1977-12

8.  Clinical studies on the correlation between immunologic status and total gastrectomy combined with splenectomy.

Authors:  M Takahashi; S Fujimoto
Journal:  Jpn J Surg       Date:  1980-06

9.  Relationship of the distribution of Leu-2+ cells with suppressor cell activities in the spleen and lymph-nodes from gastric cancer.

Authors:  T Toge; Y Seto; K Kuroi; H Yamada; K Aratani; T Fujita; E Yanagawa; T Hattori
Journal:  Jpn J Surg       Date:  1987-03

10.  The negative effect of splenectomy on the prognosis of gastric cancer.

Authors:  S Suehiro; N Nagasue; Y Ogawa; Y Sasaki; S Hirose; H Yukaya
Journal:  Am J Surg       Date:  1984-11       Impact factor: 2.565

View more
  1 in total

1.  Altered time structure of neuro-endocrine-immune system function in lung cancer patients.

Authors:  Gianluigi Mazzoccoli; Gianluigi Vendemiale; Angelo De Cata; Stefano Carughi; Roberto Tarquini
Journal:  BMC Cancer       Date:  2010-06-21       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.